Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia

First Affiliated Hospital of Suzhou Medical College35 enrolled

Overview

The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.

Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Immune Thrombocytopenic Purpura

Interventions

rapamycinDRUG

4mg oral administration on the first day, 2 mg/d oral administration for 3 months

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnoses of idiopathic thrombocytopenic purpura * Hormone and immune suppression, splenectomy is invalid Exclusion Criteria: * patients had a bad tolerance to rapamycin * platelet counts \< 10\*10E9/L during the treatment of rapamycin

Locations (1)

Jiangsu Institute of Hematology

Suzhou, Jiangsu, China

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.